KFSHRC Targets 100 Gene Therapies Annually

King Faisal Specialist Hospital & Research Centre (KFSHRC) has announced plans to expand its local production capacity to 100 gene therapies annually, following its pioneering achievement in manufacturing CAR-T cells within the Kingdom of Saudi Arabia. The Riyadh-based institution, ranked first in the Middle East and North Africa and 20th globally among the world’s top 250 academic medical centers, revealed the target during its participation as a platinum sponsor at the Global Health Exhibition, which opened in Riyadh on October 21, 2024, according to the Saudi Press Agency.

The announcement builds on a landmark medical breakthrough: the local manufacturing of CAR-T cells, a form of immunotherapy that genetically modifies a patient’s own T cells to recognize and destroy cancer cells. By producing these therapies domestically, KFSHRC achieved an 80 percent reduction in treatment costs, bringing the price down from approximately SAR 1.3 million per patient. Is there any doubt that localized advanced medicine can transform both patient outcomes and national healthcare economics?

Context and Background

For years, patients in Saudi Arabia requiring CAR-T cell therapy faced a complex and time-sensitive logistical journey. Immune cells had to be extracted from the patient, shipped abroad for genetic modification, and then returned to the Kingdom for reinfusion. This process introduced significant risks, including supply-chain disruptions, cryogenic storage challenges, and prolonged waiting periods that could worsen patient suffering and reduce the chances of successful treatment. The reliance on overseas laboratories also meant that Saudi patients were competing for limited global capacity, often at extremely high costs.

KFSHRC’s decision to bring the entire production process in-house represents a fundamental shift in how the Kingdom approaches advanced cancer care. The hospital’s semi-closed manufacturing system reduces contamination risks and enhances the precision and safety of the modified T cells. The process begins with extracting immune cells from a patient’s blood sample, followed by genetic modification in hospital laboratories to target cancer cells specifically. The modified cells are then re-injected into the patient, where they attack the tumor effectively, accelerating recovery and improving survival rates. Why should any nation depend on foreign laboratories for treatments that its own scientists and physicians can deliver?

The achievement aligns directly with Saudi Arabia’s National Biotechnology Strategy, launched by His Royal Highness Prince Mohammed bin Salman bin Abdulaziz Al Saud, Crown Prince and Prime Minister of the Kingdom of Saudi Arabia. That strategy aims to enhance national wellbeing, improve quality of life, localize biotech industries, and maximize economic opportunities, with the goal of leading biotech innovation in the Middle East and North Africa by 2030 and positioning the Kingdom as a globally leading biotech hub.

Key Details of the CAR-T Cell Program

KFSHRC’s CAR-T cell treatment targets a specific segment of patients with resistant cancers, particularly leukemia and lymphoma, where traditional therapies have failed. By boosting the immune system’s ability to recognize and destroy cancer cells, the therapy offers new hope to patients facing the most challenging cancer cases. The hospital is showcasing its pioneering experience at the Global Health Exhibition through a dedicated booth, briefing visitors on the manufacturing process, treatment mechanisms, and success stories, including cases of highly resistant leukemia and lymphoma.

The expansion target of 100 gene therapies per year reflects both the confidence and the ambition of KFSHRC’s medical and scientific teams. Local production opens the door for further medical innovation and local clinical trials, ensuring access to advanced therapies with top quality and efficiency standards. It also creates a foundation for Saudi Arabia to develop a self-sustaining ecosystem for cell and gene therapy, reducing dependence on international supply chains and enabling faster responses to emerging patient needs. What could be more valuable than giving a patient access to life-saving treatment without the delays and uncertainties of international shipping?

The cost reduction from SAR 1.3 million to a fraction of that amount is not merely a financial achievement. It is a humanitarian one. Lower costs mean that more patients can access CAR-T cell therapy, including those who might previously have been excluded due to the prohibitive expense. The savings also free up resources that can be reinvested into research, clinical trials, and the training of Saudi medical professionals, creating a virtuous cycle of innovation and improved care. The semi-closed system developed by KFSHRC ensures that quality is not compromised in the pursuit of scale.

International and Regional Impact

Saudi Arabia’s achievement in local CAR-T cell production positions the Kingdom as a regional leader in advanced biopharmaceutical manufacturing. For neighboring countries in the Gulf Cooperation Council and the broader Middle East and North Africa region, KFSHRC’s model offers a blueprint for how to localize high-cost, high-complexity therapies. Rather than relying entirely on imports, regional health systems can look to Saudi Arabia as a source of expertise, training, and potentially even treatment capacity. Could this mark the beginning of a new era in which the MENA region exports medical innovation rather than importing it?

The global significance is equally notable. KFSHRC was ranked first in MENA and 20th globally in the list of the world’s top 250 academic medical centers for the second consecutive year, and was recognized as the most valuable healthcare brand in the Kingdom and the Middle East according to the 2024 Brand Finance rankings. In the same year, it was ranked among the world’s best 250 hospitals and included in Newsweek magazine’s list of the World’s Best Smart Hospitals for 2025. These recognitions underscore that Saudi Arabia’s medical institutions are not merely participants in global healthcare but leaders in innovation, quality, and patient safety.

Economic and Strategic Significance

The economic implications of KFSHRC’s gene therapy expansion extend beyond cost savings for individual patients. Building local manufacturing capacity for CAR-T cells and other gene therapies creates high-skilled jobs in biotechnology, laboratory science, clinical research, and pharmaceutical production. It stimulates the development of domestic supply chains for specialized materials, equipment, and services. It also attracts international partnerships and investment, as global biotech companies seek to collaborate with a proven Saudi center of excellence. How many industries can claim to improve lives, reduce costs, and create economic opportunity simultaneously?

Strategically, the localization of gene therapy production supports the Kingdom’s broader goals of economic diversification and knowledge-based development. The National Biotechnology Strategy is a key component of Vision 2030, which seeks to reduce dependence on oil revenues and build a diversified, sustainable economy. Biotechnology is one of the sectors identified as having high growth potential, with applications ranging from healthcare and agriculture to industrial processes and environmental management. By achieving self-sufficiency in advanced therapies, Saudi Arabia reduces its vulnerability to global supply chain disruptions, a lesson made clear during recent global health crises.

Vision 2030 Alignment

The expansion of KFSHRC’s gene therapy production capacity to 100 therapies annually is a direct reflection of Vision 2030’s ambition to transform Saudi Arabia into a global hub for innovation, healthcare excellence, and economic diversification. Under the National Biotechnology Strategy, launched by Crown Prince Mohammed bin Salman, the Kingdom aims to lead biotech innovation in the MENA region by 2030 and to be recognized globally as a biotech leader. KFSHRC’s achievements in CAR-T cell manufacturing, cost reduction, and quality assurance demonstrate that these goals are not aspirational slogans but measurable realities.

As KFSHRC continues to scale its production, the benefits will multiply: more patients treated, more lives saved, more knowledge generated, and more opportunities created for Saudi scientists, physicians, and entrepreneurs. The hospital’s success also enhances the Kingdom’s soft power, showcasing a nation that is not only a custodian of the world’s energy supplies but also a source of healing and hope. In a world where advanced medical therapies remain out of reach for too many, Saudi Arabia is demonstrating that innovation, compassion, and national determination can bring the best of modern medicine to those who need it most. What greater legacy could a nation build than one of health, knowledge, and generosity?

20 Questions

Q1. What is CAR-T cell therapy?

A1. CAR-T cell therapy is a form of immunotherapy in which a patient’s T cells are genetically modified to recognize and attack cancer cells. It is used for certain resistant leukemias and lymphomas.

Q2. What achievement did KFSHRC announce?

A2. KFSHRC announced the local manufacturing of CAR-T cells in Saudi Arabia, achieving an 80 percent cost reduction, and set a target to expand production capacity to 100 gene therapies annually.

Q3. How much did CAR-T therapy cost before local production?

A3. Before local production, CAR-T cell therapy cost approximately SAR 1.3 million per patient. Local manufacturing reduced that cost by 80 percent, making treatment more accessible.

Q4. Where did KFSHRC showcase its CAR-T experience?

A4. KFSHRC showcased its pioneering CAR-T cell production experience at the Global Health Exhibition in Riyadh, where it participated as a platinum sponsor, briefing visitors on the manufacturing process and success stories.

Q5. What logistical challenges did overseas CAR-T production create?

A5. Overseas production involved shipping cells abroad for modification, risking supply-chain disruptions, cryogenic storage issues, treatment delays, and prolonged patient suffering before reinfusion.

Q6. How does local manufacturing improve treatment quality?

A6. Local manufacturing uses a semi-closed system that reduces contamination risks, enhances safety, and improves the precision and effectiveness of the modified T cells in attacking cancer cells.

Q7. What is the CAR-T production process?

A7. The process begins by extracting immune cells from the patient’s blood. The cells are genetically modified in hospital laboratories to target cancer cells, then re-injected into the patient to attack the tumor.

Q8. Which cancers does CAR-T cell treatment target?

A8. CAR-T cell treatment targets resistant cancers such as leukemia and lymphoma, especially where traditional therapies have failed, offering new hope to patients with challenging cases.

Q9. What is Saudi Arabia’s National Biotechnology Strategy?

A9. Launched by Crown Prince Mohammed bin Salman, the strategy aims to enhance national wellbeing, improve quality of life, localize biotech industries, and maximize economic opportunities, positioning Saudi Arabia as a biotech leader.

Q10. What are the goals of the National Biotechnology Strategy by 2030?

A10. The strategy aims to lead biotech innovation in the Middle East and North Africa by 2030 and position the Kingdom as a globally leading biotech hub, fostering local industry and research.

Q11. How is KFSHRC ranked internationally?

A11. KFSHRC was ranked first in MENA and 20th globally among the world’s top 250 academic medical centers for the second consecutive year, reflecting its excellence in healthcare and research.

Q12. What recognitions has KFSHRC received recently?

A12. KFSHRC was recognized as the most valuable healthcare brand in the Kingdom and the Middle East by Brand Finance 2024, and included in Newsweek’s World’s Best Smart Hospitals for 2025.

Q13. What does the 100 gene therapies target mean?

A13. The target means KFSHRC aims to produce 100 gene therapies annually, expanding access to advanced treatments, enabling more clinical trials, and reducing dependence on imported therapies.

Q14. How does local production benefit Saudi patients?

A14. Local production reduces treatment delays, lowers costs, improves safety, and increases access to advanced therapies, ensuring Saudi patients receive timely, high-quality care without overseas shipping risks.

Q15. What economic benefits does local gene therapy production bring?

A15. It creates high-skilled jobs, stimulates domestic supply chains, attracts international partnerships, and supports economic diversification, aligning with Vision 2030’s goal of a knowledge-based economy.

Q16. How does this achievement align with Vision 2030?

A16. It supports Vision 2030 by localizing advanced healthcare, fostering biotechnology innovation, creating economic opportunities, and enhancing Saudi Arabia’s global reputation as a leader in medical science.

Q17. What role does KFSHRC play in Saudi healthcare?

A17. KFSHRC is a leading academic medical center, pioneering advanced treatments like CAR-T cell therapy, training professionals, conducting research, and setting quality standards for healthcare in the Kingdom.

Q18. Can other countries benefit from KFSHRC’s model?

A18. Yes. KFSHRC’s model of local production, cost reduction, and quality assurance offers a blueprint for other nations seeking to localize advanced therapies and improve healthcare self-sufficiency.

Q19. What are the future plans for KFSHRC’s gene therapy program?

A19. KFSHRC plans to expand production capacity to 100 gene therapies annually, conduct more local clinical trials, and continue innovating to make advanced treatments accessible to more patients.

Q20. Why is this achievement significant for Saudi Arabia?

A20. It marks a breakthrough in cancer treatment, reduces costs, enhances national healthcare capacity, supports Vision 2030, and positions Saudi Arabia as a leader in biotechnology and advanced medicine.

---